Brainstorm Cell Therapeutics Inc (BCLI)

US · Healthcare · Biotechnology

$1.06-1.60%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.9M

EPS

$-0.19

EPS estimate

$-0.36

EPS came in at -0.19 against a street estimate of -0.36 — a beat of 47.2%.

Market cap

$11.0M

Forward P/E

0.0

P/B

54.50

Book value

$-1.05

EPS (TTM)

$-0.88

52-week high

$1.69

52-week low

$0.46

50-day MA

$1.02

200-day MA

$0.78

Beta

0.26

Analysts rate Brainstorm Cell Therapeutics Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $17.00.

Insiders

11.18%

Fund	Stake
BNP Paribas Arbitrage, SA	0.00%
VSM Wealth Advisory, LLC	0.00%
Advisor Group Holdings, Inc.	0.00%
St Germain D J Co Inc	0.00%
Steward Partners Investment Advisory, LLC	0.00%
Bangor Savings Bank	0.00%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Brainstorm Cell Therapeutics Inc — free to start.

Data updated 2026-09-18.